Evidence map›Paper›PMID 42100389›Full record

ArticleFrontiers in oncology2026

Machine-learning assisted subclassification of glioblastoma by developing an endoplasmic reticulum stress-related methylation signature.

Jinyi Zhao, Menglong Li, Xuemei Pu, Yanzhi Guo

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinyi ZhaoCollege of Chemistry, Sichuan University, Chengdu, China.
Menglong LiCollege of Chemistry, Sichuan University, Chengdu, China.
Xuemei PuCollege of Chemistry, Sichuan University, Chengdu, China.
Yanzhi GuoCollege of Chemistry, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glioblastoma (GBM) is a highly aggressive brain tumor with significant heterogeneity, leading to poor prognosis and limited treatment options. Developing innovative molecular subtyping approaches is important for gaining deeper insights into disease pathogenesis and optimizing treatment strategies. DNA methylation has been implicated in the regulation of endoplasmic reticulum stress (ERS), which disrupts protein folding and activates the unfolded protein response (UPR), ultimately determining cellular survival or apoptotic outcomes. Methods: ERS-related DNA methylation profiles were integrated with non-negative matrix factorization (NMF) to establish a molecular classification framework for GBM. An ERS-based signature was further developed using recursive feature elimination with cross-validation (RFECV), and a random forest (RF) model was constructed for subtype prediction. The model was then applied to an external TCGA cohort for validation and downstream characterization. Results: The NMF-based framework stratified GBM patients into four distinct subtypes. The RF model achieved an accuracy of 92.4% in the independent test set. Application of the model to the TCGA cohort revealed distinct molecular and clinical characteristics across subtypes. In particular, Subtype 2 was associated with an immune-inflamed phenotype, lower tumor purity, and poorer prognosis. Connectivity Map (CMap) analysis further identified MEK inhibitors as preliminary candidate compounds for specific subtypes. Discussion: These findings support an association between ERS-related epigenetic modifications and GBM heterogeneity, and provide an epigenetic framework for refined molecular stratification and further exploration of subtype-related therapeutic strategies.

Indexed as

DNA methylationendoplasmic reticulum stressglioblastomaimmune microenvironmentnon-negative matrix factorizationrandom forest

Identifiers

PMID42100389
PMCPMC13143586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.